cytosine has been researched along with Disease Models, Animal in 135 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aging is believed to affect epigenetic marking of brain DNA with 5-methylcytosine (5mC) and possibly via the 5mC to 5-hydroxymethylcytosine (5hmC) conversion by TET (ten-eleven translocation) enzymes." | 7.78 | Effect of aging on 5-hydroxymethylcytosine in the mouse hippocampus. ( Chen, H; Dzitoyeva, S; Manev, H, 2012) |
| "The effect of liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC; cidofovir) was evaluated as prophylaxis in a rabbit model of experimentally induced retinitis caused by preretinal inoculation of herpes simplex virus type 1 (HSV-1)." | 7.69 | Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis. ( Assil, KK; Bergeron-Lynn, G; Besen, G; Connor, JD; De Clercq, E; Freeman, WR; Kuppermann, BD; Munguia, D; Pursley, M; Vuong, C; Wiley, CA, 1996) |
| "Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), were evaluated for their effects on rat cytomegalovirus (RCMV)-induced interstitial pneumonitis after allogeneic bone marrow transplantation (BMTx)." | 7.68 | Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine. ( Bruggeman, CA; de Clercq, E; Havenith, M; Stals, FS; Zeytinoglu, A, 1993) |
| "The in vitro susceptibility of Candida albicans isolates to flucytosine was compared to therapeutic effect in experimental murine candidiasis (candidosis)." | 7.66 | Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. ( Bennett, JE; Polak, A; Scholer, HJ; Stevens, DA; Stiller, RL; Wall, M, 1983) |
| "Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder in which patients carry premutation alleles of 55-200 CGG repeats in the FMR1 gene." | 5.40 | Genome-wide alteration of 5-hydroxymethylcytosine in a mouse model of fragile X-associated tremor/ataxia syndrome. ( Galloway, JN; Jin, P; Lin, L; Nelson, DL; Street, RC; Wu, H; Yao, B; Zalewski, ZA, 2014) |
| " Given the potential importance of epigenetic events in hypertension, we have analyzed 5hmC and 5-methylcytosine (5mC) at single-base resolution in the renal outer medulla of the Dahl salt-sensitive rat and examined the effect of disease-relevant genetic or environmental alterations on 5hmC and 5mC patterns." | 3.80 | Base-resolution maps of 5-methylcytosine and 5-hydroxymethylcytosine in Dahl S rats: effect of salt and genomic sequence. ( Cowley, AW; Liang, M; Liu, P; Liu, Y; Yang, C, 2014) |
| "Aging is believed to affect epigenetic marking of brain DNA with 5-methylcytosine (5mC) and possibly via the 5mC to 5-hydroxymethylcytosine (5hmC) conversion by TET (ten-eleven translocation) enzymes." | 3.78 | Effect of aging on 5-hydroxymethylcytosine in the mouse hippocampus. ( Chen, H; Dzitoyeva, S; Manev, H, 2012) |
| "To evaluate(s)-1-(3-hydroxy-2-phosphonyl methoxypropyl) cytosine (HPMPC), a potent antiherpes and anticytomegalovirus drug, as a long-term treatment of experimental retinitis in rabbits." | 3.69 | Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC. ( Assil, KK; Bergeron-Lynn, G; Besen, G; De Clercq, E; Flores-Aguilar, M; Gangan, P; Kupperman, BD; Munguia, D; Pursley, M; Vuong, C, 1995) |
| "The effect of liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC; cidofovir) was evaluated as prophylaxis in a rabbit model of experimentally induced retinitis caused by preretinal inoculation of herpes simplex virus type 1 (HSV-1)." | 3.69 | Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis. ( Assil, KK; Bergeron-Lynn, G; Besen, G; Connor, JD; De Clercq, E; Freeman, WR; Kuppermann, BD; Munguia, D; Pursley, M; Vuong, C; Wiley, CA, 1996) |
| "Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), were evaluated for their effects on rat cytomegalovirus (RCMV)-induced interstitial pneumonitis after allogeneic bone marrow transplantation (BMTx)." | 3.68 | Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine. ( Bruggeman, CA; de Clercq, E; Havenith, M; Stals, FS; Zeytinoglu, A, 1993) |
| "The in vitro susceptibility of Candida albicans isolates to flucytosine was compared to therapeutic effect in experimental murine candidiasis (candidosis)." | 3.66 | Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. ( Bennett, JE; Polak, A; Scholer, HJ; Stevens, DA; Stiller, RL; Wall, M, 1983) |
| " The most common adverse events were mild gastrointestinal events and asymptomatic, transient, and reversible elevations in serum transaminases." | 2.84 | Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox. ( Brundage, T; Chittick, G; Morrison, M; Nichols, WG, 2017) |
| "Although smallpox has been eliminated from the environment, treatments are urgently being sought due to the risk of smallpox being used as a bioterrorism agent and for monkeypox virus, a zoonotic disease of Africa, and adverse reactions to smallpox virus vaccinations." | 2.47 | Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. ( Adams, MM; Foster, S; Lampert, B; Moyer, RW; Painter, G; Rice, AD; Robertson, A, 2011) |
| " Here we extend these studies by exploring different dosing regimens and performing randomized, blinded, placebo-controlled studies." | 2.47 | Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. ( Adams, MM; Burrage, AM; Foster, S; Gray, SA; Lampert, B; Lanier, R; Lindsey, SF; Manning, BR; Moyer, RW; Painter, G; Rice, AD; Robertson, A; Smith, AJ; Swetnam, D; Wallace, G, 2011) |
| "A major risk factor for eczema vaccinatum is a background of atopic dermatitis, a chronic, common allergic, relapsing disorder, manifested by dry and inflamed skin, itchy rash, Th2 biased immune response and hypersensitivity to various antigens." | 1.46 | Induction, treatment and prevention of eczema vaccinatum in atopic dermatitis mouse models. ( Achdout, H; Erez, N; Israeli, O; Israely, T; Lustig, S; Melamed, S; Paran, N; Politi, B; Tamir, H; Waner, T, 2017) |
| "However, adenovirus infections of immunocompromised patients often develop into life-threatening multi-organ disease." | 1.46 | Combination therapy with brincidofovir and valganciclovir against species C adenovirus infection in the immunosuppressed Syrian hamster model allows for substantial reduction of dose for both compounds. ( Spencer, JF; Tollefson, AE; Toth, K; Wold, WSM; Ying, B, 2017) |
| "The treatment of progressive vaccinia in individuals has involved antiviral drugs, such as cidofovir (CDV), brincidofovir, and/or tecovirimat, combined with vaccinia immune globulin (VIG)." | 1.42 | Enhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless mice. ( Dagley, A; Downs, B; Hagloch, J; Smee, DF; Tarbet, EB, 2015) |
| "Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder in which patients carry premutation alleles of 55-200 CGG repeats in the FMR1 gene." | 1.40 | Genome-wide alteration of 5-hydroxymethylcytosine in a mouse model of fragile X-associated tremor/ataxia syndrome. ( Galloway, JN; Jin, P; Lin, L; Nelson, DL; Street, RC; Wu, H; Yao, B; Zalewski, ZA, 2014) |
| " To date, a safe and effective therapy for CMV-induced hearing loss does not exist." | 1.40 | Safety of cidofovir by intratympanic delivery technique. ( Choo, DI; Nassar, M; Reece, AL; Sidell, DR; Ward, JA, 2014) |
| " We evaluated the in vivo efficacy of an orally bioavailable analog of cidofovir, hexadecyloxypropyl-cidofovir (HDP-CDV), against guinea pig CMV (GPCMV) in a guinea pig model of congenital CMV infection." | 1.37 | Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection. ( Beadle, JR; Bernstein, DI; Bravo, FJ; Cardin, RD; Hostetler, KY, 2011) |
| "We have used these biomarkers to establish the optimal dosing regimen for treatment and reveal that a single dose of 25 mg/kg of CMX001 can be efficacious at treating lethal mousepox when administered on days 4 or 5 post-infection." | 1.35 | Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001. ( Buller, RM; Lanier, R; Oberle, C; Painter, G; Parker, S; Robertson, A; Schriewer, J, 2008) |
| "Severe adenovirus infections in transplant recipients undergoing immunosuppressive therapy are of increasing concern." | 1.35 | Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection. ( De Clercq, E; Geboes, L; Kelchtermans, H; Lenaerts, L; Matthys, P; Naesens, L; Verbeken, E, 2008) |
| "With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level." | 1.33 | Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005) |
| " The objectives of this study were to expand on the results of others that cidofovir (CDV) is effective in mice inoculated with cowpox virus (CV) or vaccinia virus (VV) and to document the efficacy of single and interval dosing beginning prior to or after infection, particularly including evaluations using suboptimal doses of CDV." | 1.32 | Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. ( Collins, DJ; Kern, ER; Quenelle, DC, 2003) |
| " To improve the bioavailability of CDV, others synthesized alkoxyalkanol esters of CDV and observed >100-fold more activity than unmodified CDV against cowpox, vaccinia, and variola virus (VARV) replication." | 1.32 | Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. ( Beadle, JR; Buller, RM; Hostetler, KY; Melman, L; Owens, G; Schriewer, J, 2004) |
| " Complete cures were obtained using 1% (w/v) topical cidofovir at dosing schedules of twice daily for 8 weeks beginning at 4 weeks after CRPV infection, which represents a time when papillomas were clearly visible." | 1.31 | In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. ( Budgeon, LR; Christensen, ND; Kreider, JW; Pickel, MD, 2000) |
| "Bropirimine is an oral immunostimulant found to have efficacy in human transitional cell carcinoma in situ following the initial discovery of its antitumor activity against the murine bladder cancer MBT-2." | 1.30 | Oral bropirimine immunotherapy of rodent prostate cancer. ( Sarosdy, MF, 1997) |
| " Treatment with one dosage of HPMPC at 20 mg/kg effectively reduced virus titers." | 1.30 | Effective treatment of experimental cytomegalovirus-induced encephalo-meningitis in immunocompromised rats with HPMPC. ( Bruggeman, CA; Kloover, JS; Stals, FS; Vanagt, WY, 1997) |
| "Intravitreal cidofovir has been shown to be a long acting and highly efficacious treatment for CMV retinitis; however decrease in IOP is an adverse effect." | 1.30 | An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects. ( Banker, AS; Bergeron-Lynn, G; De Clercq, E; Flores-Aguilar, M; Freeman, WR; Keefe, K; Munguia, D; Rao, NA; Taskintuna, I; Wiley, CA, 1997) |
| "Trifluridine treatment was highly effective in this rabbit model, even when given only once a day." | 1.30 | Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis. ( Kaufman, HE; Thompson, HW; Varnell, ED, 1998) |
| " High-dose T-cin controls survived despite having received a cumulative dosage of more than twice the reported (LD(50)) mean lethal dose value." | 1.26 | Comparative study of trichothecin, amphotericin B, and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo. ( Hariri, A; Larsh, HW; Sneller, MR; Sorenson, WG, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (3.70) | 18.7374 |
| 1990's | 21 (15.56) | 18.2507 |
| 2000's | 51 (37.78) | 29.6817 |
| 2010's | 52 (38.52) | 24.3611 |
| 2020's | 6 (4.44) | 2.80 |
| Authors | Studies |
|---|---|
| Chan-Tack, K | 1 |
| Harrington, P | 1 |
| Bensman, T | 1 |
| Choi, SY | 1 |
| Donaldson, E | 1 |
| O'Rear, J | 1 |
| McMillan, D | 1 |
| Myers, L | 1 |
| Seaton, M | 1 |
| Ghantous, H | 1 |
| Cao, Y | 1 |
| Valappil, T | 1 |
| Birnkrant, D | 1 |
| Struble, K | 1 |
| Huston, J | 1 |
| Curtis, S | 1 |
| Egelund, EF | 1 |
| Delaune, D | 1 |
| Iseni, F | 1 |
| Liu, Z | 1 |
| Chen, S | 1 |
| Shan, H | 1 |
| Jia, Y | 1 |
| Chen, M | 1 |
| Song, Y | 1 |
| Lai, L | 1 |
| Li, Z | 1 |
| Liu, Y | 3 |
| Li, X | 2 |
| Li, A | 1 |
| Li, K | 1 |
| Qin, X | 1 |
| Chhatbar, K | 1 |
| Cholewa-Waclaw, J | 1 |
| Shah, R | 1 |
| Bird, A | 1 |
| Sanguinetti, G | 1 |
| Grossi, IM | 1 |
| Foster, SA | 2 |
| Gainey, MR | 1 |
| Krile, RT | 1 |
| Dunn, JA | 1 |
| Brundage, T | 2 |
| Khouri, JM | 1 |
| Pan, Z | 2 |
| Xue, ZY | 2 |
| Li, GF | 2 |
| Sun, ML | 1 |
| Zhang, M | 2 |
| Hao, LY | 2 |
| Tang, QQ | 1 |
| Zhu, LJ | 2 |
| Cao, JL | 2 |
| Toth, K | 4 |
| Spencer, JF | 4 |
| Ying, B | 3 |
| Tollefson, AE | 3 |
| Wold, WSM | 2 |
| Achdout, H | 1 |
| Lustig, S | 2 |
| Israely, T | 2 |
| Erez, N | 2 |
| Politi, B | 2 |
| Tamir, H | 1 |
| Israeli, O | 1 |
| Waner, T | 1 |
| Melamed, S | 2 |
| Paran, N | 2 |
| Brisse, E | 1 |
| Imbrechts, M | 1 |
| Mitera, T | 2 |
| Vandenhaute, J | 1 |
| Wouters, CH | 1 |
| Snoeck, R | 3 |
| Andrei, G | 3 |
| Matthys, P | 3 |
| Hosoki, K | 1 |
| Jaruga, P | 1 |
| Itazawa, T | 1 |
| Aguilera-Aguirre, L | 1 |
| Coskun, E | 1 |
| Hazra, TK | 1 |
| Boldogh, I | 1 |
| Dizdaroglu, M | 1 |
| Sur, S | 1 |
| Chen, G | 1 |
| Chen, H | 2 |
| Ren, S | 1 |
| Xia, M | 1 |
| Zhu, J | 1 |
| Zhang, L | 1 |
| Tang, L | 1 |
| Sun, L | 1 |
| Liu, H | 1 |
| Dong, Z | 1 |
| Wang, F | 1 |
| Yang, Y | 1 |
| Lin, X | 1 |
| Wang, JQ | 1 |
| Wu, YS | 1 |
| Xie, W | 1 |
| Wang, D | 1 |
| Zhu, S | 1 |
| Liao, YQ | 1 |
| Sun, Q | 1 |
| Yang, YG | 1 |
| Luo, HR | 1 |
| Guo, C | 1 |
| Han, C | 1 |
| Tang, TS | 1 |
| Lv, S | 1 |
| Wang, J | 1 |
| Dou, S | 1 |
| Yang, X | 1 |
| Ni, X | 1 |
| Sun, R | 1 |
| Tian, Z | 1 |
| Wei, H | 1 |
| Ko, YA | 1 |
| Susztak, K | 1 |
| Yao, B | 1 |
| Lin, L | 1 |
| Street, RC | 1 |
| Zalewski, ZA | 1 |
| Galloway, JN | 1 |
| Wu, H | 2 |
| Nelson, DL | 1 |
| Jin, P | 2 |
| Ward, JA | 1 |
| Sidell, DR | 1 |
| Nassar, M | 1 |
| Reece, AL | 1 |
| Choo, DI | 2 |
| De Schutter, T | 1 |
| Topalis, D | 1 |
| Duraffour, S | 1 |
| van den Oord, J | 1 |
| Liu, P | 1 |
| Yang, C | 1 |
| Cowley, AW | 1 |
| Liang, M | 1 |
| Cadena-del-Castillo, C | 1 |
| Valdes-Quezada, C | 1 |
| Carmona-Aldana, F | 1 |
| Arias, C | 1 |
| Bermúdez-Rattoni, F | 1 |
| Recillas-Targa, F | 1 |
| Olson, VA | 1 |
| Smith, SK | 1 |
| Foster, S | 4 |
| Li, Y | 2 |
| Lanier, ER | 1 |
| Gates, I | 1 |
| Trost, LC | 2 |
| Damon, IK | 1 |
| Tsenkina, Y | 1 |
| Ruzov, A | 1 |
| Gliddon, C | 1 |
| Horsburgh, K | 1 |
| De Sousa, PA | 1 |
| Smee, DF | 10 |
| Dagley, A | 1 |
| Downs, B | 1 |
| Hagloch, J | 1 |
| Tarbet, EB | 1 |
| Brush, LA | 1 |
| Black, DH | 1 |
| Mccormack, KA | 1 |
| Maxwell, LK | 1 |
| Wright, G | 1 |
| Ritchey, JW | 1 |
| Payton, ME | 1 |
| Eberle, R | 1 |
| Buller, RM | 8 |
| Wold, WS | 2 |
| Rose, ML | 1 |
| Khouri, J | 1 |
| Keilholz, L | 1 |
| Long, J | 1 |
| Godin, SJ | 1 |
| Li, S | 2 |
| Papale, LA | 2 |
| Kintner, DB | 1 |
| Sabat, G | 1 |
| Barrett-Wilt, GA | 1 |
| Cengiz, P | 1 |
| Alisch, RS | 2 |
| Haque, A | 1 |
| Hober, D | 1 |
| Blondiaux, J | 1 |
| Ledbetter, EC | 1 |
| Spertus, CB | 1 |
| Pennington, MR | 1 |
| Van de Walle, GR | 1 |
| Judd, BE | 1 |
| Mohammed, HO | 1 |
| Zhang, Q | 1 |
| Chen, K | 1 |
| Keleş, S | 1 |
| Ma, T | 1 |
| Li, YQ | 1 |
| Ding, HL | 1 |
| Ahmed, MM | 1 |
| Connor, MP | 1 |
| Palazzolo, M | 1 |
| Thompson, ME | 1 |
| Lospinoso, J | 1 |
| O'Connor, P | 1 |
| Howard, NS | 1 |
| Maturo, SC | 1 |
| Crump, R | 1 |
| Korom, M | 1 |
| Parker, S | 5 |
| Chittick, G | 1 |
| Morrison, M | 1 |
| Nichols, WG | 1 |
| Tempesta, M | 3 |
| Crescenzo, G | 3 |
| Camero, M | 3 |
| Bellacicco, AL | 3 |
| Tarsitano, E | 2 |
| Decaro, N | 1 |
| Neyts, J | 6 |
| Martella, V | 1 |
| Buonavoglia, C | 3 |
| Schultz, DA | 1 |
| Sagartz, JE | 4 |
| Huso, DL | 1 |
| Schriewer, J | 4 |
| Oberle, C | 2 |
| Robertson, A | 4 |
| Lanier, R | 4 |
| Painter, G | 5 |
| Siddiqui, AM | 1 |
| Hembrador, E | 2 |
| Inoue, H | 1 |
| Sonoda, KH | 1 |
| Ishikawa, M | 1 |
| Kadonosono, K | 1 |
| Uchio, E | 1 |
| Grayson, DR | 1 |
| Chen, Y | 1 |
| Dong, E | 1 |
| Kundakovic, M | 1 |
| Guidotti, A | 1 |
| Romanowski, EG | 5 |
| Yates, KA | 3 |
| Gordon, YJ | 6 |
| Stabenow, J | 1 |
| West, C | 1 |
| Clement, C | 1 |
| Capriotti, JA | 1 |
| Kumar, M | 1 |
| Hobden, JA | 1 |
| Foster, TP | 1 |
| Bhattacharjee, PS | 1 |
| Thompson, HW | 2 |
| Mahmud, R | 1 |
| Liang, B | 1 |
| Hill, JM | 1 |
| Marinaro, M | 1 |
| Armenise, C | 1 |
| Quenelle, DC | 3 |
| Lampert, B | 3 |
| Collins, DJ | 3 |
| Rice, TL | 1 |
| Painter, GR | 2 |
| Kern, ER | 8 |
| Bravo, FJ | 5 |
| Bernstein, DI | 4 |
| Beadle, JR | 4 |
| Hostetler, KY | 6 |
| Cardin, RD | 3 |
| Rice, AD | 3 |
| Adams, MM | 3 |
| Moyer, RW | 3 |
| Wallace, G | 1 |
| Burrage, AM | 1 |
| Lindsey, SF | 1 |
| Smith, AJ | 1 |
| Swetnam, D | 1 |
| Manning, BR | 1 |
| Gray, SA | 1 |
| Peterson, LW | 1 |
| Kim, JS | 1 |
| Kijek, P | 1 |
| Mitchell, S | 1 |
| Hilfinger, J | 1 |
| Breitenbach, J | 1 |
| Borysko, K | 1 |
| Drach, JC | 1 |
| Kashemirov, BA | 1 |
| McKenna, CE | 1 |
| Hayden, EC | 1 |
| Szulwach, KE | 1 |
| Song, CX | 1 |
| Dai, Q | 1 |
| Irier, H | 1 |
| Upadhyay, AK | 1 |
| Gearing, M | 1 |
| Levey, AI | 1 |
| Vasanthakumar, A | 1 |
| Godley, LA | 1 |
| Chang, Q | 2 |
| Cheng, X | 1 |
| He, C | 1 |
| Wang, H | 2 |
| Chhablani, J | 1 |
| Freeman, WR | 3 |
| Hartmann, K | 1 |
| Conner, L | 1 |
| Aldern, KA | 1 |
| Pearson, L | 1 |
| Cheng, L | 1 |
| Chestnut, BA | 1 |
| Price, A | 1 |
| Lesuisse, C | 1 |
| Wong, M | 1 |
| Martin, LJ | 1 |
| Verreault, D | 1 |
| Sivasubramani, SK | 1 |
| Talton, JD | 1 |
| Doyle, LA | 1 |
| Reddy, JD | 1 |
| Killeen, SZ | 1 |
| Didier, PJ | 1 |
| Marx, PA | 1 |
| Roy, CJ | 1 |
| van den Hove, DL | 2 |
| Chouliaras, L | 2 |
| Rutten, BP | 2 |
| Chen, NG | 1 |
| Hartzler, H | 1 |
| Hruby, D | 1 |
| Jordan, R | 1 |
| Painter, W | 1 |
| Mark Buller, R | 1 |
| Dzitoyeva, S | 1 |
| Manev, H | 1 |
| Huang, N | 1 |
| Tan, L | 1 |
| Xue, Z | 1 |
| Cang, J | 1 |
| Shafferman, A | 1 |
| Sierksma, AS | 1 |
| Prickaerts, J | 1 |
| Rostamian, S | 1 |
| Delbroek, L | 1 |
| Steinbusch, HW | 1 |
| Khanna, S | 1 |
| Burudkar, S | 1 |
| Bajaj, K | 1 |
| Shah, P | 1 |
| Keche, A | 1 |
| Ghosh, U | 1 |
| Desai, A | 1 |
| Srivastava, A | 1 |
| Kulkarni-Almeida, A | 1 |
| Deshmukh, NJ | 1 |
| Dixit, A | 1 |
| Brahma, MK | 1 |
| Bahirat, U | 1 |
| Doshi, L | 1 |
| Nemmani, KV | 1 |
| Tannu, P | 1 |
| Damre, A | 1 |
| B-Rao, C | 1 |
| Sharma, R | 1 |
| Sivaramakrishnan, H | 1 |
| Villar-Menéndez, I | 1 |
| Blanch, M | 1 |
| Tyebji, S | 1 |
| Pereira-Veiga, T | 1 |
| Albasanz, JL | 1 |
| Martín, M | 1 |
| Ferrer, I | 1 |
| Pérez-Navarro, E | 1 |
| Barrachina, M | 1 |
| Liekens, S | 1 |
| Tinnikov, A | 1 |
| Nordström, K | 1 |
| Thorén, P | 1 |
| Kindblom, JM | 1 |
| Malin, S | 1 |
| Rozell, B | 1 |
| Adams, M | 1 |
| Rajanayagam, O | 1 |
| Pettersson, S | 1 |
| Ohlsson, C | 1 |
| Chatterjee, K | 1 |
| Vennström, B | 1 |
| Sidwell, RW | 8 |
| Chandler, SP | 1 |
| Kansagra, P | 1 |
| Hirst, MC | 1 |
| Garneau, M | 2 |
| Bolger, GT | 1 |
| Bousquet, C | 2 |
| Kibler, P | 2 |
| Tremblay, F | 1 |
| Cordingley, MG | 2 |
| Bourne, N | 1 |
| Schleiss, MR | 3 |
| Kaneko, H | 1 |
| Mori, S | 1 |
| Suzuki, O | 1 |
| Iida, T | 1 |
| Shigeta, S | 1 |
| Abe, M | 1 |
| Ohno, S | 1 |
| Aoki, K | 1 |
| Suzutani, T | 1 |
| Owens, G | 1 |
| Melman, L | 1 |
| Leyssen, P | 1 |
| Verbeken, E | 2 |
| De Clercq, E | 14 |
| Bidanset, DJ | 3 |
| Rybak, RJ | 2 |
| Hartline, CB | 2 |
| Wan, WB | 1 |
| Bailey, KW | 4 |
| Wong, MH | 1 |
| Wandersee, MK | 2 |
| Hoffman, RM | 1 |
| Holy, A | 2 |
| Anderson, JL | 1 |
| McGregor, A | 1 |
| Teuchner, B | 1 |
| Nagl, M | 1 |
| Irschick, EU | 1 |
| Lenaerts, L | 2 |
| Naesens, L | 3 |
| Knorr, CW | 1 |
| Allen, SD | 1 |
| Torres, AR | 1 |
| Galmarini, CM | 1 |
| White, DR | 1 |
| Stroup, G | 1 |
| Kornbluth, RS | 1 |
| Snarsky, V | 1 |
| Evans, DH | 1 |
| Thiry, J | 1 |
| Thiry, E | 1 |
| Goff, A | 1 |
| Twenhafel, N | 1 |
| Garrison, A | 1 |
| Mucker, E | 1 |
| Lawler, J | 1 |
| Paragas, J | 1 |
| Fiten, P | 1 |
| Froeyen, M | 1 |
| Opdenakker, G | 1 |
| Nwanegbo, EC | 1 |
| Gambotto, A | 1 |
| Gu, Y | 1 |
| Wang, L | 1 |
| Zhou, J | 1 |
| Guo, Q | 1 |
| Liu, N | 1 |
| Ding, Z | 1 |
| Li, L | 1 |
| Liu, X | 1 |
| An, J | 1 |
| Yan, G | 1 |
| Yao, L | 1 |
| Zhang, Z | 1 |
| Kelchtermans, H | 1 |
| Geboes, L | 1 |
| Dhar, D | 1 |
| Stiller, RL | 1 |
| Bennett, JE | 1 |
| Scholer, HJ | 1 |
| Wall, M | 1 |
| Polak, A | 1 |
| Stevens, DA | 1 |
| Lotzová, E | 1 |
| Savary, CA | 1 |
| Stringfellow, DA | 1 |
| Drewinko, B | 1 |
| Gray, KN | 1 |
| Raulston, GL | 1 |
| Jardine, JH | 1 |
| Besen, G | 2 |
| Flores-Aguilar, M | 2 |
| Assil, KK | 2 |
| Kupperman, BD | 1 |
| Gangan, P | 1 |
| Pursley, M | 2 |
| Munguia, D | 3 |
| Vuong, C | 2 |
| Bergeron-Lynn, G | 3 |
| Araullo-Cruz, T | 2 |
| Stals, FS | 2 |
| Zeytinoglu, A | 1 |
| Havenith, M | 1 |
| Bruggeman, CA | 2 |
| Stanberry, LR | 1 |
| Kier, AB | 1 |
| Vogt, PE | 1 |
| Kuppermann, BD | 1 |
| Wiley, CA | 2 |
| Connor, JD | 1 |
| de Oliveira, CB | 1 |
| Stevenson, D | 1 |
| LaBree, L | 1 |
| McDonnell, PJ | 1 |
| Trousdale, MD | 1 |
| De Hauwere, B | 1 |
| Lutz, A | 1 |
| Maudgal, PC | 2 |
| Sarosdy, MF | 1 |
| Kloover, JS | 1 |
| Vanagt, WY | 1 |
| Taskintuna, I | 1 |
| Banker, AS | 1 |
| Rao, NA | 1 |
| Keefe, K | 1 |
| Oostra, BA | 1 |
| Hoogeveen, AT | 1 |
| Kaufman, HE | 1 |
| Varnell, ED | 1 |
| Bolger, G | 1 |
| Lapeyre, N | 1 |
| Rhéaume, M | 1 |
| Cordingley, M | 1 |
| Duan, J | 1 |
| Paris, W | 1 |
| De Marte, J | 1 |
| Roopchand, D | 1 |
| Fleet, TL | 1 |
| Christensen, ND | 1 |
| Pickel, MD | 1 |
| Budgeon, LR | 1 |
| Kreider, JW | 1 |
| Lenzo, JC | 1 |
| Shellam, GR | 1 |
| Lawson, CM | 1 |
| Cohen, J | 1 |
| Sande, MA | 1 |
| Bowman, CR | 1 |
| Calderone, RA | 1 |
| Sneller, MR | 1 |
| Hariri, A | 1 |
| Sorenson, WG | 1 |
| Larsh, HW | 1 |
| Hamilton, JD | 1 |
| Elliott, DM | 1 |
| Balzarini, J | 1 |
| Morris, JL | 1 |
| Leonhardt, JA | 1 |
| Mead, JR | 1 |
| Romanowski, E | 1 |
| Zia, S | 1 |
| Hyde, DM | 1 |
| Giri, SN | 1 |
| Warren, RP | 1 |
| Morrey, JD | 1 |
| Burger, RA | 1 |
| Okleberry, KM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| European Randomised Clinical Trial on mPOX Infection[NCT06156566] | Phase 4 | 150 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for cytosine and Disease Models, Animal
| Article | Year |
|---|---|
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation.
Topics: Animals; Antiviral Agents; Cytosine; Disease Eradication; Disease Models, Animal; Drug Approval; Hum | 2021 |
Brincidofovir: A Novel Agent for the Treatment of Smallpox.
Topics: Animals; Antiviral Agents; Cytomegalovirus; Cytosine; Disease Models, Animal; Hematopoietic Stem Cel | 2023 |
Drug Development against Smallpox: Present and Future.
Topics: Animals; Antiviral Agents; Benzamides; Biological Warfare Agents; Biomedical Research; Cytosine; Dis | 2020 |
Epigenomics: the science of no-longer-junk DNA. Why study it in chronic kidney disease?
Topics: Animals; Chromatin Immunoprecipitation; Cytosine; Disease Models, Animal; DNA Methylation; Epigenomi | 2013 |
Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.
Topics: Amides; Amidines; Androstenes; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antiviral | 2015 |
Progress in the discovery of compounds inhibiting orthopoxviruses in animal models.
Topics: Adenine; Animals; Antiviral Agents; Benzamides; Cidofovir; Cytosine; Disease Models, Animal; Drug Di | 2008 |
From trans-methylation to cytosine methylation: evolution of the methylation hypothesis of schizophrenia.
Topics: Animals; Brain; Cytosine; Disease Models, Animal; DNA Methylation; Epigenesis, Genetic; Evolution, M | 2009 |
Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Topics: Animals; Antiviral Agents; Bioterrorism; Cytosine; Disease Models, Animal; Disease Transmission, Inf | 2011 |
Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Topics: Animals; Antiviral Agents; Cytosine; Disease Models, Animal; Disease Transmission, Infectious; Dose- | 2011 |
The role of growth factors, angiogenic enzymes and apoptosis in neovascularization and tumor growth-collected publications.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cidofovir; Cycloh | 2002 |
A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
Topics: Animals; Antiviral Agents; Bioterrorism; Cidofovir; Cytosine; Disease Models, Animal; Humans; Mice; | 2003 |
Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; DNA Virus Infection | 2003 |
Antiviral therapy for adenovirus infections.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Animals; Antiviral Agents; Cidofovir; Cytosine; D | 2006 |
Animal model for fragile X syndrome.
Topics: Animals; Carrier Proteins; Codon; Cytosine; Disease Models, Animal; Fragile X Mental Retardation Pro | 1997 |
Cidofovir in the treatment of poxvirus infections.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; | 2002 |
Value of animal models to evaluate agents with potential activity against human cytomegalovirus.
Topics: Acyclovir; Animals; Antiviral Agents; Cell Division; Cell Survival; Cells, Cultured; Cidofovir; Cyto | 1991 |
1 trial available for cytosine and Disease Models, Animal
| Article | Year |
|---|---|
Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox.
Topics: Adenoviridae; Adolescent; Adult; Animals; Antiviral Agents; Cytomegalovirus; Cytosine; Disease Model | 2017 |
118 other studies available for cytosine and Disease Models, Animal
| Article | Year |
|---|---|
Efficient base editing with high precision in rabbits using YFE-BE4max.
Topics: Albinism; Animals; Base Sequence; Cytidine Deaminase; Cytosine; Disease Models, Animal; Embryo, Mamm | 2020 |
UHPLC Q-Exactive MS-based spleen metabolomics and lipidomics to explore the effect mechanisms of Danggui Buxue Decoction in anemia mice.
Topics: Anemia; Animals; Biomarkers; Chromatography, High Pressure Liquid; Cytosine; Disease Models, Animal; | 2020 |
Quantitative analysis questions the role of MeCP2 as a global regulator of alternative splicing.
Topics: Alternative Splicing; Animals; Brain; Cytosine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltran | 2020 |
Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits.
Topics: Animals; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Body Temperature; Body Weigh | 2017 |
DNA Hydroxymethylation by Ten-eleven Translocation Methylcytosine Dioxygenase 1 and 3 Regulates Nociceptive Sensitization in a Chronic Inflammatory Pain Model.
Topics: 5-Methylcytosine; Animals; Chronic Pain; Cytosine; Dioxygenases; Disease Models, Animal; DNA Methyla | 2017 |
HAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model.
Topics: A549 Cells; Adenoviridae Infections; Adenovirus Infections, Human; Adenoviruses, Human; Animals; Ant | 2017 |
Induction, treatment and prevention of eczema vaccinatum in atopic dermatitis mouse models.
Topics: Animals; Antibodies, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; Cidofovir; Cytosine; Derma | 2017 |
Combination therapy with brincidofovir and valganciclovir against species C adenovirus infection in the immunosuppressed Syrian hamster model allows for substantial reduction of dose for both compounds.
Topics: Adenoviridae Infections; Adenoviruses, Human; Animals; Antiviral Agents; Cytosine; Disease Models, A | 2017 |
Lytic viral replication and immunopathology in a cytomegalovirus-induced mouse model of secondary hemophagocytic lymphohistiocytosis.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Dexamethasone; Disease Models, Animal; Humans; Immun | 2017 |
The spectre of smallpox lingers.
Topics: Animals; Benzamides; Cytosine; Disease Eradication; Disease Models, Animal; Disease Reservoirs; Drug | 2018 |
Excision release of 5?hydroxycytosine oxidatively induced DNA base lesions from the lung genome by cat dander extract challenge stimulates allergic airway inflammation.
Topics: Allergens; Animals; Biomarkers; Cats; Chromatography, Gas; Cytosine; Disease Models, Animal; DNA Dam | 2018 |
Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Animals; Azacitidine; Cytosine; Diabetic Nephropathies; | 2019 |
Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's disease.
Topics: 5-Methylcytosine; Animals; Brain; Corpus Striatum; Cytosine; Disease Models, Animal; DNA Methylation | 2013 |
Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection.
Topics: Animals; Cells, Cultured; Cytosine; Dendritic Cells; Disease Models, Animal; Guanosine; Hepatitis B; | 2014 |
Genome-wide alteration of 5-hydroxymethylcytosine in a mouse model of fragile X-associated tremor/ataxia syndrome.
Topics: 5-Methylcytosine; Animals; Ataxia; Base Sequence; Cerebellum; Consensus Sequence; Cytosine; Disease | 2014 |
Safety of cidofovir by intratympanic delivery technique.
Topics: Animals; Antiviral Agents; Cidofovir; Cochlea; Cytomegalovirus Infections; Cytosine; Disease Models, | 2014 |
Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Apoptosis; Cell Line, Tumor; Cidofovir; Cytosine; | 2013 |
Base-resolution maps of 5-methylcytosine and 5-hydroxymethylcytosine in Dahl S rats: effect of salt and genomic sequence.
Topics: 5-Methylcytosine; Animals; Base Sequence; CpG Islands; Cytosine; Disease Models, Animal; Epigenomics | 2014 |
Age-dependent increment of hydroxymethylation in the brain cortex in the triple-transgenic mouse model of Alzheimer's disease.
Topics: 5-Methylcytosine; Age Factors; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein | 2014 |
In vitro efficacy of brincidofovir against variola virus.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Cidofovir; Cytosine; Disease Models, Ani | 2014 |
White matter tract and glial-associated changes in 5-hydroxymethylcytosine following chronic cerebral hypoperfusion.
Topics: 5-Methylcytosine; Animals; Autophagy-Related Proteins; Calcium-Binding Proteins; Cerebrovascular Dis | 2014 |
Enhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless mice.
Topics: Administration, Topical; Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Dru | 2015 |
Papiine herpesvirus 2 as a predictive model for drug sensitivity of Macacine herpesvirus 1 (monkey B virus).
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Cidofovir; Cytosine; Disease Models, Animal; Gancic | 2014 |
Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model.
Topics: Adenoviridae Infections; Adenoviruses, Human; Alanine Transaminase; Animals; Body Weight; Cell Line; | 2014 |
The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease.
Topics: Animals; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Cidofovir; Cytosine; Disease | 2015 |
Hippocampal increase of 5-hmC in the glucocorticoid receptor gene following acute stress.
Topics: 3' Untranslated Regions; 5-Methylcytosine; Acute Disease; Animals; Cytosine; Disease Models, Animal; | 2015 |
In Vitro and In Vivo Evaluation of Cidofovir as a Topical Ophthalmic Antiviral for Ocular Canine Herpesvirus-1 Infections in Dogs.
Topics: Administration, Ophthalmic; Animals; Antiviral Agents; Chlorocebus aethiops; Cidofovir; Cytosine; Di | 2015 |
Genome-wide disruption of 5-hydroxymethylcytosine in a mouse model of autism.
Topics: 5-Methylcytosine; Animals; Autistic Disorder; Corpus Striatum; Cytosine; Disease Models, Animal; DNA | 2015 |
Hydroxymethylation of microRNA-365-3p Regulates Nociceptive Behaviors via Kcnh2.
Topics: 5-Methylcytosine; Animals; Cytosine; Dioxygenases; Disease Models, Animal; DNA Methylation; DNA-Bind | 2016 |
Effect of high-dose vocal fold injection of cidofovir and bevacizumab in a porcine model.
Topics: Animals; Bevacizumab; Biopsy, Needle; Cidofovir; Cytosine; Disease Models, Animal; Dose-Response Rel | 2017 |
Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
Topics: Animals; Antiviral Agents; Cytosine; Disease Models, Animal; DNA, Viral; Ectromelia virus; Ectromeli | 2017 |
Assessing the efficacy of cidofovir against herpesvirus-induced genital lesions in goats using different therapeutic regimens.
Topics: Animals; Antiviral Agents; Base Sequence; Cidofovir; Cytosine; Disease Models, Animal; DNA Primers; | 2008 |
Experimental infection of an African dormouse (Graphiurus kelleni) with monkeypox virus.
Topics: Animal Structures; Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Hemorrhag | 2009 |
Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
Topics: Alanine Transaminase; Animals; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Cell Line; | 2008 |
Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Cytokines; Cytosine; Disease Models, Ani | 2009 |
Clinical evaluation of local ocular toxicity in candidate anti-adenoviral agents in vivo.
Topics: Adenoviridae Infections; Animals; Antiviral Agents; Cidofovir; Conjunctiva; Conjunctivitis, Viral; C | 2009 |
The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections.
Topics: Adenoviridae Infections; Adenoviruses, Human; Administration, Topical; Animals; Antiviral Agents; Ci | 2009 |
A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.
Topics: Animals; Antiviral Agents; Benzamides; Cytosine; Disease Models, Animal; Female; Humans; Isoindoles; | 2010 |
Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis.
Topics: Adenoviridae; Adenoviridae Infections; Animals; Anti-Infective Agents, Local; Cidofovir; Conjunctiva | 2011 |
Cidofovir does not prevent caprine herpesvirus type-1 neural latency in goats.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; DNA, Viral; Female; Ganglia; | 2010 |
Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies.
Topics: Administration, Oral; Animals; Antiviral Agents; Cytosine; Disease Models, Animal; Drug Evaluation, | 2010 |
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
Topics: Administration, Oral; Animals; Antiviral Agents; Cytomegalovirus Infections; Cytosine; Disease Model | 2011 |
Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir.
Topics: Administration, Oral; Alanine; Animals; Antiviral Agents; Cells, Cultured; Cidofovir; Cytomegaloviru | 2011 |
Biodefence since 9/11: The price of protection.
Topics: Animals; Antiviral Agents; Biomedical Research; Bioterrorism; Budgets; Cytosine; Disease Models, Ani | 2011 |
5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging.
Topics: 5-Methylcytosine; Aging; Analysis of Variance; Animals; Animals, Newborn; Cerebellum; Chromosome Del | 2011 |
Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug.
Topics: Animals; Chromatography, High Pressure Liquid; Ciliary Body; Cytomegalovirus Retinitis; Cytosine; De | 2011 |
Epigenetic regulation of motor neuron cell death through DNA methylation.
Topics: 5-Methylcytosine; Age Factors; Amyloid Precursor Protein Secretases; Amyotrophic Lateral Sclerosis; | 2011 |
Evaluation of inhaled cidofovir as postexposure prophylactic in an aerosol rabbitpox model.
Topics: Administration, Inhalation; Animals; Antiviral Agents; Cell Line; Cidofovir; Cytosine; Disease Model | 2012 |
The role of 5-hydroxymethylcytosine in aging and Alzheimer's disease: current status and prospects for future studies.
Topics: 5-Methylcytosine; Aging; Alzheimer Disease; Animals; Cytosine; Disease Models, Animal; DNA Methylati | 2012 |
Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Topics: Animals; Benzamides; Biomarkers, Pharmacological; Cell Line; Cytosine; Disease Models, Animal; Drug | 2012 |
Effect of aging on 5-hydroxymethylcytosine in the mouse hippocampus.
Topics: 5-Methylcytosine; Aging; Alzheimer Disease; Animals; Arachidonate 5-Lipoxygenase; Cytosine; Disease | 2012 |
Reduction of DNA hydroxymethylation in the mouse kidney insulted by ischemia reperfusion.
Topics: 5-Methylcytosine; Animals; Chemokine CXCL10; Cytosine; Dioxygenases; Disease Models, Animal; DNA Met | 2012 |
A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Ectromeli | 2012 |
Behavioral and neurobiological effects of prenatal stress exposure in male and female APPswe/PS1dE9 mice.
Topics: 5-Methylcytosine; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavioral Symptoms; B | 2013 |
Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia.
Topics: Administration, Oral; Animals; Cytosine; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2012 |
Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.
Topics: 5-Methylcytosine; 5' Untranslated Regions; Adult; Aged; Aged, 80 and over; Animals; Corpus Striatum; | 2013 |
Retardation of post-natal development caused by a negatively acting thyroid hormone receptor alpha1.
Topics: Animals; Arginine; Cytosine; Disease Models, Animal; Flow Cytometry; Genes, Dominant; Genome; Growth | 2002 |
Fragile X (CGG)n repeats induce a transcriptional repression in cis upon a linked promoter: evidence for a chromatin mediated effect.
Topics: Animals; Chromatin; Cytosine; Disease Models, Animal; Enzyme Inhibitors; Fragile X Syndrome; Gene Ex | 2003 |
HPMPC therapy of MCMV-induced retinal disease in the SCID mouse measured by electroretinography, a non-invasive technique.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Disease Models, Animal; E | 2003 |
Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Cidofovir; Cowpox; Cowpox virus; Cytosine; Disease | 2003 |
An animal model of neonatal cytomegalovirus infection.
Topics: Animals; Animals, Newborn; Antiviral Agents; Body Weight; Brain; Cytomegalovirus; Cytomegalovirus In | 2003 |
The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir.
Topics: Adenoviridae Infections; Adenoviruses, Human; Administration, Topical; Animals; Antigens, Viral; Ant | 2004 |
Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.
Topics: Administration, Oral; Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Dose-R | 2004 |
Efficacy of cidofovir in a murine model of disseminated progressive vaccinia.
Topics: Administration, Topical; Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; DNA | 2004 |
Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.
Topics: Administration, Cutaneous; Animals; Antiviral Agents; Cidofovir; Cowpox; Cowpox virus; Cytosine; Dis | 2004 |
Efficacy of ganciclovir and cidofovir against human cytomegalovirus replication in SCID mice implanted with human retinal tissue.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cytosine; Disease | 2004 |
Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.
Topics: Administration, Oral; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infecti | 2004 |
Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice.
Topics: Administration, Topical; Animals; Antiviral Agents; Brain; Cidofovir; Cyclophosphamide; Cytosine; Di | 2004 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; | 2005 |
Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice.
Topics: Animals; Cells, Cultured; Cidofovir; Cytosine; Disease Models, Animal; Drug Resistance; Mice; Mice, | 2005 |
Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection.
Topics: Animals; Animals, Newborn; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; | 2006 |
Cyclic cidofovir (cHPMPC) prevents congenital cytomegalovirus infection in a guinea pig model.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Female; Guinea Pigs; Infecti | 2006 |
N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model.
Topics: Adenoviridae; Adenoviridae Infections; Animals; Antiviral Agents; Cidofovir; Cornea; Cytosine; Disea | 2006 |
Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection.
Topics: Animals; Antiviral Agents; Cidofovir; Cowpox; Cytokines; Cytosine; Disease Models, Animal; Female; L | 2006 |
Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Carcinoma, Non-S | 2006 |
The effect of cidofovir on cytomegalovirus-induced hearing loss in a Guinea pig model.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Disease Models, Animal; | 2006 |
Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Chlorocebus aethiops; Cidofovir; Cytosine; Di | 2006 |
Cidofovir is effective against caprine herpesvirus 1 infection in goats.
Topics: Animals; Cidofovir; Cytosine; Disease Models, Animal; Goats; Herpesviridae Infections; Organophospho | 2007 |
In vivo imaging of cidofovir treatment of cowpox virus infection.
Topics: Animals; Antiviral Agents; Bioterrorism; Chlorocebus aethiops; Cidofovir; Cowpox; Cowpox virus; Cyto | 2007 |
A model of human cytomegalovirus infection in severe combined immunodeficient mice.
Topics: Animals; Antiviral Agents; Cell Culture Techniques; Cell Line; Cidofovir; Cytomegalovirus; Cytomegal | 2007 |
Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Humans; Organophosphonates; | 2007 |
DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions.
Topics: Adenine; Animals; Antiviral Agents; Chlorocebus aethiops; Cidofovir; Cytosine; Disease Models, Anima | 2007 |
Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Administration, Topical; Animals; Antiviral Agent | 2007 |
A naturally-occurring mutation in Cacna1f in a rat model of congenital stationary night blindness.
Topics: Adaptation, Ocular; Amino Acid Sequence; Animals; Calcium Channels; Cytosine; Dark Adaptation; Disea | 2008 |
Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection.
Topics: 3T3 Cells; Adenoviridae; Adenoviridae Infections; Animals; Antibodies, Viral; Antiviral Agents; Cell | 2008 |
Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model.
Topics: Adenoviridae; Adenoviridae Infections; Animals; Antiviral Agents; Cricetinae; Cytosine; Disease Mode | 2008 |
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model.
Topics: Animals; Candida albicans; Candidiasis; Cytosine; Disease Models, Animal; Dose-Response Relationship | 1983 |
Analysis of natural killer cell activity in random-bred Rowett athymic rats.
Topics: Animals; Cytosine; Cytotoxicity, Immunologic; Disease Models, Animal; Immunity, Innate; Immunologic | 1984 |
Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Electroretinography; Eye Inf | 1995 |
HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model.
Topics: Administration, Topical; Animals; Antiviral Agents; Cells, Cultured; Chlorocebus aethiops; Cidofovir | 1994 |
Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice.
Topics: Animals; Antiviral Agents; Brain; Cidofovir; Cytosine; Disease Models, Animal; Dose-Response Relatio | 1993 |
Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine.
Topics: Animals; Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Cidofovir; Cytomegalovirus; | 1993 |
Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs.
Topics: Acyclovir; Administration, Topical; Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, | 1993 |
Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Drug Carriers; Eye Infection | 1996 |
Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.
Topics: Adenoviridae Infections; Adenoviruses, Human; Animals; Antibodies, Viral; Cidofovir; Cytosine; Disea | 1996 |
An ocular model of Adenovirus type 5 infection in the rabbit.
Topics: Adenine; Adenoviridae; Adenoviridae Infections; Animals; Antiviral Agents; Cidofovir; Cytosine; Dise | 1995 |
Oral bropirimine immunotherapy of rodent prostate cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Cytosin | 1997 |
Effective treatment of experimental cytomegalovirus-induced encephalo-meningitis in immunocompromised rats with HPMPC.
Topics: Animals; Antiviral Agents; Brain; Cidofovir; Cytomegalovirus Infections; Cytosine; Disease Models, A | 1997 |
An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects.
Topics: Animals; Cidofovir; Ciliary Body; Corneal Diseases; Cytosine; Disease Models, Animal; Eye Diseases; | 1997 |
Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis.
Topics: Acyclovir; Animals; Antiviral Agents; Cidofovir; Cornea; Cytosine; Disease Models, Animal; Female; G | 1998 |
Acute murine cytomegalovirus infection: a model for determining antiviral activity against CMV induced hepatitis.
Topics: Alanine Transaminase; Animals; Antiviral Agents; Aspartate Aminotransferases; Body Weight; Cidofovir | 1999 |
Topical effects of cidofovir on cutaneous rabbit warts: treatment regimen and inoculum dependence.
Topics: Administration, Topical; Animals; Antiviral Agents; Cidofovir; Cottontail rabbit papillomavirus; Cyt | 2000 |
In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas.
Topics: Animals; Antiviral Agents; Cidofovir; Cottontail rabbit papillomavirus; Cytosine; Disease Models, An | 2000 |
Ganciclovir and cidofovir treatment of cytomegalovirus-induced myocarditis in mice.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Ganciclovir; Herpesviridae I | 2001 |
Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Cidofovir; Cowpox virus; Cytosine; Disease Mo | 2001 |
Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Disease | 2001 |
Bioterrorism. Blocking smallpox: a second defense.
Topics: Animals; Antiviral Agents; Bioterrorism; Cidofovir; Cytosine; Disease Models, Animal; Disease Outbre | 2001 |
Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model.
Topics: Adenoviridae Infections; Adenoviruses, Human; Animals; Antiviral Agents; Cidofovir; Conjunctivitis, | 2001 |
Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug.
Topics: Animals; Antiviral Agents; Area Under Curve; Body Weight; Chlorocebus aethiops; Cidofovir; Cowpox; C | 2002 |
Experimental Candida albicans endocarditis: characterization of the disease and response to therapy.
Topics: Agglutinins; Amphotericin B; Animals; Antibodies, Fungal; Aortic Valve; Candida albicans; Candidiasi | 1977 |
Comparative study of trichothecin, amphotericin B, and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo.
Topics: Amphotericin B; Animals; Cryptococcosis; Cryptococcus; Cryptococcus neoformans; Cytosine; Disease Mo | 1977 |
Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice.
Topics: Amphotericin B; Animals; Cryptococcosis; Cryptococcus; Cryptococcus neoformans; Cytosine; Disease Mo | 1975 |
Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Disease Models, Animal; | 1992 |
Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine.
Topics: Animals; Antifungal Agents; Antineoplastic Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; | 1992 |
Pretreatment with topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model.
Topics: Adenoviridae; Adenoviridae Infections; Animals; Antiviral Agents; Cidofovir; Colony Count, Microbial | 1992 |
Effects of an interferon inducer bropirimine on bleomycin-induced lung fibrosis in hamsters.
Topics: Animals; Bleomycin; Body Weight; Bronchoalveolar Lavage Fluid; Collagen; Cricetinae; Cytosine; Disea | 1992 |
Murine retroviral disease-enhancing effects of a pyrimidinone immunomodulator.
Topics: Acquired Immunodeficiency Syndrome; Adjuvants, Immunologic; Administration, Oral; Animals; Antineopl | 1992 |
(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis.
Topics: Animals; Antiviral Agents; Bromodeoxyuridine; Cidofovir; Cytosine; Disease Models, Animal; Drug Admi | 1991 |